Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two‐Cohort, Phase Ib/II Trial

BACKGROUND: Both protracted irinotecan and antiangiogenesis therapy have shown promising efficacy against Ewing sarcoma (EWS). METHODS: Patients diagnosed with recurrent or refractory EWS were enrolled and further categorized into cohort A (≥16 years) or cohort B (<16 years). In the dose‐defining...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jie, Xie, Lu, Sun, Xin, Liu, Kuisheng, Tang, Xiaodong, Yan, Taiqiang, Yang, Rongli, Guo, Wei, Gu, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Sarcomas
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265337/
https://www.ncbi.nlm.nih.gov/pubmed/33611805
http://dx.doi.org/10.1002/onco.13726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265337/
https://www.ncbi.nlm.nih.gov/pubmed/33611805
http://dx.doi.org/10.1002/onco.13726

Ejemplares similares